Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Astellas Pharma Inc.
Industry Sector: HealthTechnology
CEO: Naoki Okamura
Number Of Employees: 14,754
Enterprise Value: $23,970,201,923
PE Ratio: -39.61
Exchange/Ticker 1: Tokyo:4503
Exchange/Ticker 2: N/A
Latest Market Cap: $15,911,258,158
BioCentury | Apr 7, 2025
Deals
Latest capsid deal gives a lifeline to Sangamo: Deals Report
Plus: Sanofi gains license to another Nurix program; Allakos takes Tang/Concentra buyout offer
BioCentury | Feb 7, 2025
Editor's Commentary
Has interest in ADCs peaked? — a Perspective
Pfizer’s drop of a late-stage ADC this week may signal the ADC frenzy is cooling
BioCentury | Feb 5, 2025
Management Tracks
Management changes at Astellas
Plus: Lundbeck board planning to elect Dorothea Wenzel chair, and updates from PacBio and Uvax Bio
BioCentury | Jan 18, 2025
Politics, Policy & Law
Diabetes, cancer drugs dominate CMS’s new price negotiation list
Ozempic tops list of 15 drugs whose negotiated prices will take effect in 2027
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Dec 5, 2024
Product Development
Stem cell therapy companies take different roads to reproducibility
But they agree that creating a reliable product is necessary for scalability
BioCentury | Dec 5, 2024
Discovery & Translation
Science Spotlight: Advances in RSV and hMVP vaccines
BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates
BioCentury | Nov 26, 2024
Deals
Roche rewards Poseida’s shareholders with high premium in $1B takeout
If fulfilled, CVR tied to pipeline programs would drive deal’s value even further
BioCentury | Nov 25, 2024
Product Development
Elevidys isn’t slowing innovation in DMD gene therapy
Two gene therapies for Duchenne muscular dystrophy advance to Phase III as a preclinical program attracts pharma acquisition
BioCentury | Nov 16, 2024
Data Byte
EMA’s CHMP finds path to Leqembi nod, backs three other new drugs
Eleven label expansions also among committee’s November recommendations
Items per page:
1 - 10 of 2372